Trial
NCT02513667
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Novartis Pharmaceuticals
Condition
ALK-positive Non-small Cell Lung Cancer
Intervention
Ceritinib
Why stopped
The study was terminated after UTSW was informed by Novartis that further support for the study would not be provided
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-03